MetaCap

Outset Medical (OM) vs Stereotaxis (STXS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Outset Medical (OM) has outperformed Stereotaxis (STXS) over the past year, losing 34.5% versus a loss of 59.4%. Over five years, STXS leads with a -84.2% price change compared with -99.6% for OM. Stereotaxis is the larger company by market cap ($95.0 million vs $53.0 million), about 1.8 times the size.

Stereotaxis converts more of its revenue into profit, with a net margin of -66.8% versus -68.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OM-34.50%STXS-59.39%
+37%-16%-70%
Nov 21, 20251 yearNov 20, 2026
OM-99.62%STXS-85.37%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OM versus STXS key metrics
MetricOMSTXS
Share price$2.81$0.9422
Market cap$53.03M$95.03M
1-day change-3.44%-6.71%
YTD return-24.26%-59.03%
1-year return-34.50%-59.39%
5-year return-99.61%-84.16%
EPS (TTM)$-3.78$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$119.48M$32.38M
Revenue growth (YoY)+5.09%+20.28%
Net income (latest FY)$-81.65M$-21.64M
Gross margin39.13%52.73%
Operating margin-55.83%-68.30%
Net margin-68.34%-66.85%
52-week high$6.49$2.86
52-week low$2.77$0.80
Distance from 52-week high-56.70%-67.06%
Analyst consensusbuynone
Avg. price target upside+172.95%+218.40%
Average volume140.40K715.12K
Shares outstanding18.87M100.86M
Employees310131
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OM has outperformed STXS by 24.9 percentage points over the past year.
  • Stereotaxis grew revenue faster in its latest fiscal year (+20.28% vs +5.09%).

About Outset Medical

OM stock →

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 310 employees

About Stereotaxis

STXS stock →

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees

OM vs STXS FAQ

Which is bigger, Outset Medical or Stereotaxis?

Stereotaxis (STXS) is larger, with a market capitalization of $95.03M compared with $53.03M for Outset Medical (OM).

Which stock has performed better over the past year, OM or STXS?

OM returned -34.50% over the past 12 months, compared with -59.39% for STXS (price return, excluding dividends). Past performance does not predict future results.

Are Outset Medical and Stereotaxis in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons